

File reference	W17FOI245
Key words	Medicine usage
Date of release	10/08/2017
Attachments	Yes L3

Freedom of Information Act Disclosure log - Reply Extract

You asked

- 1. Within your trust how many patients have been treated with the following products in the past 3 months you have available;**

	No. pts treated between 1/3/17 to 31/5/17
Treatment	
MabThera IV (rituximab)	89
MabThera SC (rituximab)	12
Truxima (rituximab)	10
Gazyvaro (obinutuzumab)	0
Imbruvica (ibrutinib)	16
Zydelig (idelalisib)	0
Arzerra (ofatumumab)	6

- 2. Please can you state the number of patients for the above drugs for the following indications;**

The nature of your request will biographically identify patients currently in treatment. This short time frame lowers the numbers affected and this in turn prevents some disclosures. As you have also requested total numbers in question one the Trust cannot use five or fewer figures or provide higher figures as the public could easily deduce the numbers. Therefore the Trust is refusing to supply figures for specific drug by indication. This is in accordance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i), the personal information exemption as described in the Freedom of Information Act.

	Number of patients treated between 1/3/17 to 31/5/17				
Treatment	Follicular lymphoma [C82.0 to	Diffuse Large B-cell	Chronic Lymphocytic Leukaemia	All other B-cell, haematological malignancies	Rheumatoid Arthritis [M5

	C82.9]	Lymphom a [C83.3]	[C91.1]	(all C82, C83, C85, C88.0, C88.4 codes not listed above]	and M6]
MabThera IV (rituximab)	7	15	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)	47
MabThera SC (rituximab)	12	0	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)	0
Truxima (rituximab)	0	0	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)	10
Gazyvaro (obinutuzumab)	0	0	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)	0
Imbruvica (ibrutinib)	0	0	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)	0
Zydelig (idelalisib)	0	0	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)	0
Arzerra (ofatumumab)	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)	Refused in compliance with section 40.-(2)

3. Does your trust code haematological malignancies against ICD10 codes?

Yes